文献速递免疫规划传染病防控与疫情报告

三抗原乙型肝炎疫苗在健康年轻成人中快速实现高血清保护率:IV期研究结果

Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study.
PubMed 文献 · Vaccine · 2021-01-13

主要终点为第7月血清保护率(SPR)≥95%,实际第3月即达98.8%(95%CI:93.7%,99.7%),第7月高应答比例97.6%,疫苗安全耐受。

要点

  • 第3月SPR达98.8%,即两剂后已快速获得高血清保护率。
  • 第7月高应答比例(anti-HBs≥100 mIU/mL)达97.6%。
  • GMC从第3月413.6 mIU/mL升至第7月6799.9 mIU/mL。

核心结论

  • 新参考标准批次的TAV成功通过资格认证,显示出有效性、良好的安全性特征以及快速的血清保护作用,包括两剂后即出现保护。

主要发现

  • 主要终点在第3月(第二剂后2月)即达到,SPR为98.8%(95%CI:93.7%,99.7%)。
  • 第3月和7月高应答比例分别为81.4%和97.6%。
  • 第3月和7月GMC分别为413.6 mIU/mL和6799.9 mIU/mL。
  • TAV安全且耐受良好。

关键数值与推荐

  • 主要终点为第7月SPR≥95%,实际第3月SPR达98.8%(95%CI:93.7%,99.7%)。
  • 高应答定义为anti-HBs滴度≥100 mIU/mL。

临床怎么用

  • 健康年轻成人接种TAV后两剂即可快速获得高血清保护率,可考虑用于需要快速免疫保护的场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sci-B-Vac® is a tri-antigenic recombinant Hepatitis B vaccine (TAV) containing the small (s), medium (pre-S2) and large (pre-S1) hepatitis B surface (HBs) antigens. To comply with vaccine licensure, a new reference standard batch was qualified by characterizing the seroprotection rate (SPR) for anti-HBs titers ≥10 mIU/mL, following vaccination. METHODS: Ninety-one healthy adults aged 20-40 years were enrolled in an open label, single-arm phase IV study receiving three IM doses of 10 μg TAV at 0, 1 and 6 months. Immunogenicity was evaluated monthly and at 7, 9 and 12 months. The primary endpoint to qualify the reference standard was an SPR ≥95% by month 7. Secondary endpoints were proportion of high responders (anti-HBs titers ≥100 mIU/mL) and geometric mean concentrations (GMC) of HBs antibodies each month. Participants were followed for safety to month 12. RESULTS: The primary endpoint was met 2 months after the second dose at month 3 [SPR 98.8%; 95% CI: 93.7%, 99.7%]. Proportion of high responders at months 3 and 7 were 81.4% and 97.6%, respectively. GMC at months 3 and 7 were 413.6 mIU/mL and 6799.9 mIU/mL, respectively. TAV was safe and well-tolerated. CONCLUSIONS: The new reference standard batch of TAV was qualified successfully, demonstrating efficacy, a favorable safety profile and a rapid onset of seroprotection, including after two vaccine doses. Clinical trial registry: NCT04179786.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Atsmon J, Machluf N, Yayon-Gur V, et al. Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study. Vaccine. 2021. PMID: 33451780. doi:10.1016/j.vaccine.2020.12.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。